Association between raised IL-8 serum levels and resistance to combined peg-interferon plus ribavirin therapy in HCV+ active chronic hepatitis
| Autor: | Cacopardo, Bruno Santi, Nigro, L, Nunnari, G, LA MEDICA, G, Cappellani, Alessandro, Palermo, Filippo, Cappello, E, Russo, R. |
|---|---|
| Jazyk: | italština |
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Time Factors Genotype ribavirin Drug Resistance Enzyme-Linked Immunosorbent Assay Hepacivirus Interferon alpha-2 Antiviral Agents Polyethylene Glycols Peg-IFN Humans chronic hepatitis C IL-8 Peg-IFN ribavirin chronic hepatitis C IL-8 Interleukin-8 Interferon-alpha Hepatitis C Chronic Recombinant Proteins Treatment Outcome Data Interpretation Statistical RNA Viral Drug Therapy Combination Female Biomarkers Follow-Up Studies |
| Popis: | IL-8 serum levels were measured in a group of 44 patients affected with Chronic Active Hepatitis (CAH) HCV+ at the beginning and end of peg-interferon plus ribavirin combined therapy. IL-8 levels were compared with those measured in a group of healthy controls. The patients were treated for 12 months, and then followed up for 6 months after the end of the therapy. IL-8 serum levels were detected by ELISA at the beginning and end of the therapy, and then at the end of the follow-up. IL-8 serum levels were significantly more elevated (p0.01) in CAH HCV+ patients than in the healthy controls. Furthermore, IL-8 serum levels in those patients who subsequently showed a sustained virological response to the therapy, declined on treatment and maintained lower levels than in those who did not respond to therapy. Serum IL-8 can be considered and proposed as a non-invasive and predictive marker of response to combined PEG IFN alpha2b + Ribavirin in CAH HCV +. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|